Antibody-drug conjugate (ADC)technology is not new. The first ADC, Pfizer Inc.’s Mylotarg, reached the market two decades ago. The field has undergone slow but transformative enhancements.
“ADC development has historically not been without its setbacks,” Datamonitor Healthcare analysts noted in a 2019 report. The concept of delivering a potent cytotoxic payload directly to tumor cells and causing minimum damage to non-tumor cells was viewed as a significant advance towards precision medicine, but it proved difficult to translate into the clinic